Shares of Conatus Pharmaceuticals Inc. skyrocketed in the extended session Monday after the microcap biotech announced a licensing and collaboration agreement with Novartis AG for a liver disease treatment. Conatus shares surged 150% to $4.90 after hours on heavy volume.